Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
Anticancer Res. 2023 Aug;43(8):3679-3683. doi: 10.21873/anticanres.16550.
BACKGROUND/AIM: This study evaluated the efficacy of nivolumab and pembrolizumab in treating platinum-sensitive recurrent or metastatic head and neck squamous cell carcinomas (R/M-HNSCC).
Platinum-sensitive patients with R/M-HNSCC were selected at Tokyo Medical University Hospital from May 1, 2017, to June 30, 2022. Patients with a history of treatment with nivolumab or pembrolizumab were included. Nivolumab was used in 21 cases and pembrolizumab in 15 cases.
The median overall survival (OS) was 16.9 months in the nivolumab group and 19.2 months in the pembrolizumab group and no significant differences were observed between the two groups. The median progression-free survival (PFS) was 4.8 months in the nivolumab group and 9.3 months in the pembrolizumab group. No significant differences were observed between the two groups. The objective response rates (ORR) were 38% and 47% in the nivolumab and pembrolizumab groups, respectively.
Nivolumab as well as pembrolizumab were found to be effective in platinum-sensitive patients with R/M-HNSCC. Nivolumab can be considered a potential treatment option for platinum-sensitive R/M-HNSCC in the future.
背景/目的：本研究评估了纳武利尤单抗和帕博利珠单抗在治疗铂敏感复发性或转移性头颈部鳞状细胞癌（R/M-HNSCC）中的疗效。
本研究从 2017 年 5 月 1 日至 2022 年 6 月 30 日，从东京医科大学医院选择了铂敏感的 R/M-HNSCC 患者。入组患者为既往接受过纳武利尤单抗或帕博利珠单抗治疗的患者。纳武利尤单抗组 21 例，帕博利珠单抗组 15 例。
纳武利尤单抗组的中位总生存期（OS）为 16.9 个月，帕博利珠单抗组为 19.2 个月，两组间无显著差异。纳武利尤单抗组的中位无进展生存期（PFS）为 4.8 个月，帕博利珠单抗组为 9.3 个月。两组间无显著差异。纳武利尤单抗组和帕博利珠单抗组的客观缓解率（ORR）分别为 38%和 47%。
纳武利尤单抗和帕博利珠单抗在铂敏感的 R/M-HNSCC 患者中均显示出疗效。纳武利尤单抗将来可能成为铂敏感 R/M-HNSCC 的一种潜在治疗选择。
